hTERT promoter activity identifies osteosarcoma cells with increased EMT characteristics

Oncology Letters

Volumn 7, Issue 1, 2014, Pages 239-244

  Yu, Ling ^a   Liu, Shiqing ^a   Guo, Weichun ^a   Zhang, Chun ^a   Zhang, Bo ^a   Yan, Huichao ^b   Wu, Zheng ^c  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Human telomerase reverse transcriptase; Osteosarcoma; Telomerase

Indexed keywords

LENTIVIRUS VECTOR; TELOMERASE REVERSE TRANSCRIPTASE; VIMENTIN;

ARTICLE; CELL INVASION; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MESENCHYME CELL; OSTEOSARCOMA; OSTEOSARCOMA CELL; POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

EID: 84888413145     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1692     Document Type: Article

References (31)

1. Savage SA and Mirabello L: Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011: 548151, 2011.
2. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543, 2009.
3. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
4. De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110, 2013.
5. Bastid J: EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev 31: 277-283, 2012.
6. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
7. May CD, Sphyris N, Evans KW, Werden SJ, Guo W and Mani SA: Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 13: 202, 2011.
8. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S and Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888, 2008.
9. Bacchetti S and Counter C: Telomeres and telomerase in human cancer (review). Int J Oncol 7: 423-432, 1995.
10. Meyerson M: Role of telomerase in normal and cancer cells. J Clin Oncol 18: 2626-2634, 2000.
11. Gomez DE, Armando RG, Farina HG, et al: Telomere structure and telomerase in health and disease (review). Int J Oncol 41: 1561-1569, 2012.
12. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
13. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB and Dome JS: Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 22: 3790-3797, 2004.
14. Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791, 1997.
15. Hiyama E, Hiyama K, Yokoyama T and Shay JW: Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia 3: 17-26, 2001.
16. Liu Z, Li Q, Li K, et al: Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 32: 4203-4213, 2013.
17. Wick M, Zubov D and Hagen G: Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 232: 97-106, 1999.
18. Takakura M, Kyo S, Kanaya T, et al: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59: 551-557, 1999.
19. Cong YS, Wen J and Bacchetti S: The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8: 137-142, 1999.
20. Niinaka Y, Harada K, Fujimuro M, et al: Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res 70: 9483-9493, 2010.
21. Funasaka T, Hu H, Yanagawa T, Hogan V and Raz A: Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res 67: 4236-4243, 2007.
22. Funasaka T, Hogan V and Raz A: Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer. Cancer Res 69: 5349-5356, 2009.
23. Kirkpatrick KL, Clark G, Ghilchick M, Newbold RF and Mokbel K: hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur J Surg Oncol 29: 321-326, 2003.
24. Saretzki G, Petersen S, Petersen I, Kolble K and von Zglinicki T: hTERT gene dosage correlates with telomerase activity in human lung cancer cell lines. Cancer Lett 176: 81-91, 2002.
25. Ito H, Kyo S, Kanaya T, Takakura M, Inoue M and Namiki M: Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res 4: 1603-1608, 1998.
26. Shigeishi H, Sugiyama M, Tahara H, et al: Increased telomerase activity and hTERT expression in human salivary gland carcinomas. Oncol Lett 2: 845-850, 2011.
27. Gibbs CP Jr, Levings PP and Ghivizzani SC: Evidence for the osteosarcoma stem cell. Curr Orthop Pract 22: 322-326, 2011.
28. Siclari VA and Qin L: Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 5: 78, 2010.
29. Marian CO, Cho SK, McEllin BM, et al: The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 16: 154-163, 2010.
30. Kirkpatrick KL, Newbold RF and Mokbel K: The mRNA expression of hTERT in human breast carcinomas correlates with VEGF expression. J Carcinog 3: 1, 2004.
31. Park JI, Venteicher AS, Hong JY, et al: Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460: 66-72, 2009.